GlassScriptPhysician profile
Nathan W Uy
NPI 1437148954
$5,069.86
in general payments reported to CMS, 2019-2025
54 companies · $704 in 2025
The $704 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $126 · 2021: $669 · 2022: $119 · 2023: $1,937 · 2024: $1,155 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Travel and Lodging: $1,474 · Education: $23.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.79 |
| Travel and Lodging | $1,473.65 |
| Education | $23.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $2,130.62 | 2021-2024 | Elekta Medical Linear Accelerator, Elekta Unity |
| Elekta LTD | $712.28 | 2023 | Elekta Medical Linear Accelerator, Elekta Unity |
| Novartis Pharmaceuticals Corporation | $240.70 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $126.06 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $119.64 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Genentech USA, INC. | $98.69 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Visionrt, INC. | $97.81 | 2019 | |
| Pfizer INC. | $92.80 | 2020-2025 | |
| Veran Medical Technologies, INC. | $83.99 | 2020 | |
| Alexion Pharmaceuticals, INC. | $82.79 | 2023-2024 | Ultomiris |
| Sobi, INC | $61.89 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.05 | 2019-2025 | |
| Array Biopharma INC | $60.96 | 2025 | Braftovi, Lorbrena, Xalkori |
| Regeneron Healthcare Solutions, INC. | $59.74 | 2024-2025 | Libtayo |
| Janssen Biotech, INC. | $53.21 | 2019-2024 | Rybrevant |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Uy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.